Home /
Drugs / INFLUENZA A VIRUS A/WEST VIRGINIA/30/2022 (H1N1) RECOMBINANT HEMAGGLUTININ ANTIGEN, INFLUENZA A VIRUS A/District of Columbia/27/2023 (H3N2) RECOMBINANT HEMAGGLUTININ ANTIGEN, and INFLUENZA B VIRUS B/AUSTRIA/1359417/2021 RECOMBINANT HEMAGGLUTININ ANTIGEN
INFLUENZA A VIRUS A/WEST VIRGINIA/30/2022 (H1N1) RECOMBINANT HEMAGGLUTININ ANTIGEN, INFLUENZA A VIRUS A/District of Columbia/27/2023 (H3N2) RECOMBINANT HEMAGGLUTININ ANTIGEN, and INFLUENZA B VIRUS B/AUSTRIA/1359417/2021 RECOMBINANT HEMAGGLUTININ ANTIGEN
FDA Drug Profile — FLUBLOK TRIVALENT NORTHERN HEMISPHERE
Drug Details
- Generic Name
- INFLUENZA A VIRUS A/WEST VIRGINIA/30/2022 (H1N1) RECOMBINANT HEMAGGLUTININ ANTIGEN, INFLUENZA A VIRUS A/District of Columbia/27/2023 (H3N2) RECOMBINANT HEMAGGLUTININ ANTIGEN, and INFLUENZA B VIRUS B/AUSTRIA/1359417/2021 RECOMBINANT HEMAGGLUTININ ANTIGEN
- Brand Names
- FLUBLOK TRIVALENT NORTHERN HEMISPHERE
- Application Number
- BLA125285
- Sponsor
- Sanofi Pasteur Inc.
- NDC Codes
- 1
- Dosage Forms
- INJECTION
- Routes
- INTRAMUSCULAR
- Active Ingredients
- INFLUENZA A VIRUS A/DISTRICT OF COLUMBIA/27/2023 (H3N2) RECOMBINANT HEMAGGLUTININ ANTIGEN, INFLUENZA A VIRUS A/WEST VIRGINIA/30/2022 (H1N1) RECOMBINANT HEMAGGLUTININ ANTIGEN, INFLUENZA B VIRUS B/AUSTRIA/1359417/2021 RECOMBINANT HEMAGGLUTININ ANTIGEN